Idelalisib Approved for Marketing Phase N/A Trials for Chronic Lymphocytic Leukaemia (CLL)

IndicationsStatusPurposePhase
Approved for MarketingNot AvailableNot Available
clinicaltrials.gov IdentifierTitleDrugs
NCT02136511Expanded Access for Idelalisib in Combination With Rituximab in Chronic Lymphocytic Leukemia